BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 37231905)

  • 1. Clinical Features of Non-Alcoholic Fatty Liver Disease in the Non-Lean Population.
    Li MR; Li JZ; Li JY; Wang CC; Yuan RK; Ye LH; Liu YY; Liang XJ; Zhang HC; Liu ZQ; Zeng DY; Zhang XD; Wang DH; Li JQ; Li TY; Yang L; Cao Y; Pan Y; Lin XG; Pan CQ; Dai EH; Dong ZY
    Obes Facts; 2023; 16(5):427-434. PubMed ID: 37231905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Characteristics and Metabolic Profiles of Non-Alcoholic Fatty Liver Disease (NAFLD) in Lean Patients and Their Comparison with Obese and Overweight NAFLD.
    Chakrabarty M; Jha AN; Sharma DJ
    J Assoc Physicians India; 2022 Apr; 70(4):11-12. PubMed ID: 35443531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Different predictors of steatosis and fibrosis severity among lean, overweight and obese patients with nonalcoholic fatty liver disease.
    Shao C; Ye J; Li F; Feng S; Wang W; Zhong B
    Dig Liver Dis; 2019 Oct; 51(10):1392-1399. PubMed ID: 30928418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of body mass index on clinicopathological features of nonalcoholic fatty liver disease in Taiwan.
    Lin CL; Tai CM; Huang JF; Liu CJ; Chen HF; Cheng PN; Chen CY; Peng CY; Wang CC; Weng SH; Tseng TC; Kao JH
    J Gastroenterol Hepatol; 2022 Oct; 37(10):1901-1910. PubMed ID: 35790343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liver-related Mortality is Increased in Lean Subjects with Non- alcoholic Fatty Liver Disease Compared to Overweight and Obese Subjects.
    Feldman A; Wernly B; Strebinger G; Eder SK; Zandanell S; Niederseer D; Strasser M; Haufe H; Sotlar K; Paulweber B; Datz C; Aigner E
    J Gastrointestin Liver Dis; 2021 Sep; 30(3):366-373. PubMed ID: 34375373
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of lean patients with nonalcoholic fatty liver disease: potential role of high hemoglobin levels.
    Akyuz U; Yesil A; Yilmaz Y
    Scand J Gastroenterol; 2015 Mar; 50(3):341-6. PubMed ID: 25540973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity.
    Fracanzani AL; Petta S; Lombardi R; Pisano G; Russello M; Consonni D; Di Marco V; Cammà C; Mensi L; Dongiovanni P; Valenti L; Craxì A; Fargion S
    Clin Gastroenterol Hepatol; 2017 Oct; 15(10):1604-1611.e1. PubMed ID: 28554682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Lipid metabolism in non-alcoholic fatty liver disease in patients with different body weights in mid-mountain conditions].
    Toktogulova NA; Sultanalieva RB; Tuhvatshin RR; Kaliev TK
    Ter Arkh; 2023 Jan; 94(12):1361-1366. PubMed ID: 37167179
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of clinical and metabolic profiles of lean versus non-lean nonalcoholic fatty liver disease.
    Navarroza AMC; Wong SN
    Indian J Gastroenterol; 2021 Aug; 40(4):380-388. PubMed ID: 34213749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distinctive clinical and genetic features of lean vs overweight fatty liver disease using the UK Biobank.
    Chahal D; Sharma D; Keshavarzi S; Arisar FAQ; Patel K; Xu W; Bhat M
    Hepatol Int; 2022 Apr; 16(2):325-336. PubMed ID: 35178663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systematic review with meta-analysis: the significance of histological disease severity in lean patients with nonalcoholic fatty liver disease.
    Sookoian S; Pirola CJ
    Aliment Pharmacol Ther; 2018 Jan; 47(1):16-25. PubMed ID: 29083036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lean-non-alcoholic fatty liver disease increases risk for metabolic disorders in a normal weight Chinese population.
    Feng RN; Du SS; Wang C; Li YC; Liu LY; Guo FC; Sun CH
    World J Gastroenterol; 2014 Dec; 20(47):17932-40. PubMed ID: 25548491
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adiponectin-leptin ratio for the early detection of lean non-alcoholic fatty liver disease independent of insulin resistance.
    Lu CW; Yang KC; Chi YC; Wu TY; Chiang CH; Chang HH; Huang KC; Yang WS
    Ann Med; 2023 Dec; 55(1):634-642. PubMed ID: 36790383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating future risk of NAFLD in adolescents: a prediction and decision curve analysis.
    Abeysekera KWM; Orr JG; Gordon FH; Howe LD; Hamilton-Shield J; Heron J; Hickman M
    BMC Gastroenterol; 2022 Jun; 22(1):323. PubMed ID: 35773644
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of body mass index on disease progression and outcomes in patients with nonalcoholic fatty liver disease.
    Biswas S; Vaishnav M; Farooqui N; Aggarwal A; Pathak P; Yadav R; Das P; Elhence A; Goel A; Mishra AK; Shalimar
    Postgrad Med J; 2023 Sep; 99(1176):1094-1103. PubMed ID: 37308443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of risk factors for non-alcoholic fatty liver disease in hospitalized children with obesity before the late puberty stage.
    Zhou L; Zhang L; Zhang L; Yi W; Yu X; Mei H; Xiao H; Wang Y; Qin H; Xiong X; Yan S; Dong H; Chen P; Chen X
    Front Endocrinol (Lausanne); 2023; 14():1224816. PubMed ID: 37720532
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Triglyceride Glucose Index and Related Parameters (Triglyceride Glucose-Body Mass Index and Triglyceride Glucose-Waist Circumference) Identify Nonalcoholic Fatty Liver and Liver Fibrosis in Individuals with Overweight/Obesity.
    Khamseh ME; Malek M; Abbasi R; Taheri H; Lahouti M; Alaei-Shahmiri F
    Metab Syndr Relat Disord; 2021 Apr; 19(3):167-173. PubMed ID: 33259744
    [No Abstract]   [Full Text] [Related]  

  • 18. Natural History of Nonalcoholic Fatty Liver Disease With Normal Body Mass Index: A Population-Based Study.
    Ahmed OT; Gidener T; Mara KC; Larson JJ; Therneau TM; Allen AM
    Clin Gastroenterol Hepatol; 2022 Jun; 20(6):1374-1381.e6. PubMed ID: 34265444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-obese or lean non-alcoholic fatty liver disease was associated with increased risk of cancer in patients with type 2 diabetes mellitus.
    Chen N; Zhou J; Wang K; Li X; Li Z
    BMJ Open Diabetes Res Care; 2023 Feb; 11(1):. PubMed ID: 36792168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Noninvasive fibrosis tools in NAFLD: validation of APRI, BARD, FIB-4, NAFLD fibrosis score, and Hepamet fibrosis score in a Portuguese population.
    Rigor J; Diegues A; Presa J; Barata P; Martins-Mendes D
    Postgrad Med; 2022 May; 134(4):435-440. PubMed ID: 35332833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.